Zosano Pharma Announces Issuance of U.S. Patent for Method of Rapidly Achieving Therapeutic Levels with M207 for the Acute Treatment of Migraine
July 20, 2021 at 08:30 am EDT
Zosano Pharma Corporation announced that it has been granted an additional patent covering method of use of M207 with the issuance of U.S. Patent No. 11,058,630 titled Method of Rapidly Achieving Therapeutic Concentrations of Triptans for the Treatment of Migraines. The newly issued patent covers methods for the release of active drug from Zosano’s microneedle system in about one minute and reaching potentially therapeutic levels as quickly as 30 minutes upon application. This latest patent adds to Zosano’s M207 patent portfolio, which now includes two U.S. patents with claims covering composition of matter and method of use for M207 with expirations in 2037.